← Home / Aclaris Therapeutics, Inc. (ACRS)
Stock Analysis
Aclaris Therapeutics, Inc. (ACRS)
ACRS
ACRS · Market data
5.20 -2.26%
Track ACRS in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ACRS price is:
52W Range Position
88%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-02 16:44 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 5.71. Holding above 5.05 keeps the current thesis intact.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
5.05
↗
Break Above
Confirmation improves above resistance.
5.71
🎯
Next Objective
Pattern-derived target if setup continues.
6.23
×
Thesis Break
Scenario weakens below invalidation.
Below 5.05
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
7
●
Financial Results
HIGH
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
(NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2026 and provided a corporate and clinical update .
8-K Filing • SEC EDGAR
APR
28
◈
Strategic Agreement
HIGH
Clinical Pipeline Update:
These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations.
8-K Filing • SEC EDGAR
What's Driving ACRS?
📈 Technical recovery is improving
Momentum is Neutral. Watch 5.71 for confirmation and 5.05 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 5.05 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Pattern
Double Bottom · Confirmed
Trigger
5.15
Target
6.23
Invalidation
4.01
RSI(14)
48.1
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 5.05 and resistance around 5.31. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
ACRS — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$726.2M
Company size
EV
$708.4M
Debt-adjusted value
P/E
-10.4
Not meaningful
P/S
86.8
Very high
P/B
5.1
Balanced
EV/Sales
84.7
Very high
EV/EBIT
-8.8
Not meaningful
P/FCF
-13.9
Not meaningful
FCF Yield
-7.20%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
2.00M
↗ Strong
📈 Net Income
-19.82M
↘ Negative
🧮 EPS (Basic)
-0.15
↘ Negative
Aclaris Therapeutics, Inc.
Related Opportunities